BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 wit

    Press/Media: Public Engagement Activities › Professional

    Period14-Oct-2024

    Media coverage

    1

    Media coverage

    • TitleBioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 wit
      Degree of recognitionInternational
      Media name/outletAcrofan [ENG]
      Media typeWeb
      Country/TerritoryUnited States
      Date14/10/2024
      URLhttps://us.acrofan.com/detail.php?number=973337
      PersonsHiddo Lambers Heerspink
    View all 1
    View less